Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Factor IX - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights ...

Hemophilia B treatment typically involves regular factor IX infusions. The latest research includes two gene therapy drugs that may reduce the need for these infusions. Though research is still ...

Following are specific recommended plasma levels and actions for common bleeding problems and clinical situations which occur with Hemophilia B, also known as Factor IX Deficiency: Assess situation ...

AMT-061, an AAV5 vector containing factor IX (FIX)-Padua variant, has been shown to increase FIX activity to threshold FIX levels sufficient to significantly reduce the risk of bleeding events without ...

Review the side-effects of Factor IX as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Learn everything you need to know about Factor IX-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Factor IX concentrate products ( Table 1) may be used to manage an acute hemorrhage or to decrease the risk of bleeding associated with surgery in patients with hemophilia B. Before factor IX ...

VON Willebrand's disease is manifested by a deficiency of factor VIII (antihemophilic factor) and a prolonged bleeding time and is inherited as an autosomal dominant trait of variable penetrance. 1 ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . A single infusion of verbrinacogene setparvovec resulted in normal factor IX levels among all 10 men who ...

A commercially prepared plasma concentrate was administered in six infusions to four patients with factor IX deficiency. All showed a distinct rise in the factor IX level. On the basis of the ...